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Following Proton Radiation Therapy
Bree R. Eaton†* , Shannon M. MacDonald , Torunn I. Yock and Nancy J. Tarbell
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Radiation-induced secondary malignancies are a significant, yet uncommon cause of 
morbidity and mortality among cancer survivors. Secondary malignancy risk is depen-
dent upon multiple factors including patient age, the biological and genetic predispo-
sition of the individual, the volume and location of tissue irradiated, and the dose of 
radiation received. Proton therapy (PRT) is an advanced particle therapy with unique 
dosimetric properties resulting in reduced entrance dose and minimal to no exit dose 
when compared with standard photon radiation therapy. Multiple dosimetric studies in 
varying cancer subtypes have demonstrated that PRT enables the delivery of adequate 
target volume coverage with reduced integral dose delivered to surrounding tissues, and 
modeling studies taking into account dosimetry and radiation cell biology have estimated 
a significantly reduced risk of radiation-induced secondary malignancy with PRT. Clinical 
data are emerging supporting the lower incidence of secondary malignancies after PRT 
compared with historical photon data, though longer follow-up in proton treated cohorts 
is awaited. This article reviews the current dosimetric and clinical literature evaluating the 
incidence of and risk factors associated with radiation-induced secondary malignancy 
following PRT.
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inTRODUCTiOn
Radiation-induced secondary malignancies are a rare, yet significant late effect of radiation treat-
ment among cancer survivors. The second malignancy risk is dependent upon the patient’s age, the 
radiation dose received and volume of normal tissue irradiated, as well as the patients’ family history 
of cancer and unique biological risk for malignancy (1, 2). As the risk is life-long and cumulative, 
children and young adults expected to survive many decades following definitive cancer therapy are at 
greatest risk for developing a radiation-induced malignancy. Long-term follow-up of the Childhood 
Cancer Survivor Study has demonstrated that there has been an increase in mortality attributed to 
second malignancies over time and the death rate due to a subsequent malignancy exceeds that due 
to all other causes at 25 years after first cancer diagnosis (3, 4). Retrospective series of large cohorts 
of pediatric patients treated with older photon radiotherapy techniques have reported a cumulative 
incidence of second malignancies ranging from 9.3 to 19% at 30 years (1, 5, 6), which can have 
profound effects on patient quality of life and mortality (4–6).
Proton therapy (PRT) is an advanced radiation technique now used with the hope of reducing 
late effects of radiotherapy. A proton beam has a unique dose-deposition pattern characterized by 
reduced entrance dose and minimal to no exit dose compared with conventional photon irradiation 
(7). Treating with protons gives the radiation oncologist the ability to maintain target volume coverage 
FiGURe 1 | Dose distributions for a proton (left) and photon (right) craniospinal plan prescribed to 23.4 Gy (relative biological equivalents) are 
illustrated for comparison. The proton craniospinal plan provides considerable sparing of normal tissues anterior to the spinal canal and delivers a significantly 
reduced total integral dose to the patient.
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required for efficacious therapy, while minimizing dose delivered 
to nearby normal tissues (8). A primary expected benefit of this 
decrease in dose to normal tissues is reduced risk of secondary 
malignancies (9) as well as other radiation-induced acute and 
late effects. In this article, we will review selected dosimetric and 
clinic data addressing the impact of PRT treatment on secondary 
malignancy risk.
DOSiMeTRiC COMPARiSOnS
In a treatment planning comparison study evaluating PRT in 
comparison to standard photon techniques and intensity-modu-
lated radiation therapy (IMRT) for a variety of malignancies, the 
use of protons has been demonstrated to substantially reduce the 
volume of normal tissues receiving medium to low doses (below 
about 70% of the target dose) when compared with both standard 
and IMRT photon plans (8). Over all cases, the use of protons 
lead to a reduction of the total integral dose by a factor of three 
compared to standard photon techniques and at least a factor of 
two compared to intensity-modulated photon plans (8). Many 
similar dosimetric comparison studies have been performed for 
a variety of specific tumor types among children and adults and 
have clearly demonstrated the superior ability of PRT to spare 
normal tissues from unwanted radiation (9–12). With the use 
of craniospinal irradiation for medulloblastoma, the dosimetric 
benefit of protons is particularly striking as organs anterior to 
the vertebrae are spared from receiving unwanted radiation with 
PRT (12) (Figure 1). In effort to quantify the effect of the reduced 
total integral dose delivered with PRT on secondary malignancy 
risk, studies have further utilized modeling systems based on 
dosimetric comparisons, organ equivalent dose, and radiation 
protection models to approximate the benefit of protons with 
regard to second malignancies.
In an analysis of pediatric rhabdomyosarcoma and medul-
loblastoma cases, Miralbell et  al. (13) analyzed the dosimetry 
of conventional photons, IMRT, and scattered and scanned 
proton plans and estimated secondary cancer risk according 
to the International Commission on Radiologic Protection 
(ICRP). Results revealed that proton plans reduced the expected 
incidence of radiation-induced secondary cancers for the rhab-
domyosarcoma case by a factor ≥2 and for the medulloblastoma 
case by a factor of 8–15 when compared with either IMRT or 
conventional X-ray plans (13). Furthermore, cost-effectiveness 
analysis which has included the risk of secondary malignan-
cies for patients with medulloblastoma has shown that proton 
treatment is associated with higher quality adjusted life years 
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and reduced cost, in part due to the estimations of reduced 
incidence of secondary malignancies (14, 15). In a similar study 
from Moteabbed et  al. (16), dose distributions from passive 
scattered protons, pencil bean scanning protons, and IMRT and 
volumetric-modulated arc therapy (VMAT) photon plans for six 
pediatric patients with brain and head-and-neck tumors were 
used to calculate the excess absolute risk (EAR) and lifetime 
attributable risk (LAR) for developing a second tumor in the soft 
tissue and skull. The LAR for IMRT/VMAT relative to proton 
plans ranged from 1.3 to 4.6 for soft tissue and from 3.5 to 9.5 
for the skull. Larger absolute LAR was observed for younger 
patients and when using linear risk models (16). Paganetti et al. 
(17) used phantom data and a sophisticated risk model based 
on cell kill, mutation, repopulation, and inhomogeneous organ 
doses to estimate the LAR of second malignancy within the 
RT field for representative cases of optic glioma and vertebral 
body Ewing’s sarcoma on a 4- and 14-year-old fully contoured 
phantom. This study found that protons may reduce the risk of 
second malignancy by a factor ranging from 2 to 10 and also 
demonstrated that LAR was affected by different methods of 
proton RT planning (17).
Multiple other dosimetric and secondary risk modeling studies 
have been performed for adult malignancies with similar results. 
In a dosimetric comparison between PRT and IMRT among 
11 patients with low-grade glioma prescribed 54 Gy (RBE), the 
equivalent uniform dose delivered to adjacent normal tissues was 
found to be 10–20 Gy lower with protons (18). Using biological 
modeling of radiation induced toxicities, the mean ratio for excess 
risk of radiation induced second tumors with IMRT as compared 
to protons was found to be 2.2 (range 1.6–6.5). The mean excess 
risk of a PRT induced second tumor in the brain per 10,000 cases 
per year was 47 (range 11–83), while the mean risk for IMRT was 
106 (range 70–134) (18). In an analysis of conventional parallel 
opposed and intensity-modulated photon and proton treatment 
plans for a patient with Hodgkin’s disease, spot scanning PRT was 
found to decrease the secondary malignancy risk by a factor of 
2 based on the ICRP calculation scheme and normal tissue dose 
distribution (19).
Yoon et  al. (20) used ion chambers and CR-39 detectors to 
measure the secondary dose delivered to tissues outside of the 
target volume (measured at 20–60 cm from the isocenter) during 
irradiation with IMRT and PRT for patients with prostate and 
head-and-neck cancer and estimated organ-specific radiation-
induced cancer risk by applying organ equivalent dose estima-
tions to dose distributions. The average secondary doses for 
prostate patients ranged between 3 and 1  mSv/Gy with IMRT, 
which was approximately one order of magnitude higher than for 
PRT. Although the average secondary doses of IMRT were higher 
than those of PRT for head-and-neck cancers, these differences 
were not significant. Organ equivalent dose calculations showed 
that, for prostate cancer patients, the risk of secondary cancers 
in out-of-field organs, such as the stomach, lungs, and thyroid, 
was at least five times higher for IMRT than for PRT (20). A 
second dosimetric comparison among prostate cancer patients 
evaluating protons and 6 MV IMRT photon plans was performed 
by Fontenot et al. (21), and the secondary malignancy risk was 
estimated by taking into account both primary and secondary 
contributions to total dose delivered on an organ-specific basis 
and using risk models from the Committee on the Biological 
Effects of Ionizing Radiation. It was found that PRT reduced the 
risk of a secondary malignancy by 26–39% compared with IMRT, 
which was attributed to the substantial sparing of the rectum and 
bladder by the PRT plans in this study (21).
neUTROn SCATTeR
Secondary dose from neutron scatter produced during radio-
therapy contributes to the total effective dose delivered to the 
patient and the secondary malignancy risk but is not accounted 
for in most dosimetric comparisons. The neutron scatter with 
PRT results from protons losing energy as they interact with the 
range modulator and apertures (22). In some circumstances, 
neutron dose delivered outside of target tissues with passively 
scattered protons has been estimated to be much greater than 
with either scanned PRT, intensity modulated, or conventional 
photon treatment (23). This has sparked controversy about the 
effect of PRT on secondary malignancy risk and the relative 
benefit of pencil beam scanning vs. passive scattering proton 
treatment (22–26).
The neutron dose equivalent with pencil beam scanning for 
a medium size target volume can reach approximately 1% of the 
treatment dose in the region of the Bragg peak (27). In non-target 
tissues of the patient, the neutron dose contributes approximately 
0.004 and 0.002  Sv/treatment Gy, for large and medium target 
volumes, respectively, a factor which is about two times that of 
photon therapy (26). However, because this dose delivered to the 
non-target area from neutron scatter is far less than that resulting 
from primary dose fall-off, multiple authors have concluded that 
primary dosimetric comparisons are sufficient for estimation of 
secondary malignancy risk. Thus, the total integral dose delivered 
to the patient remains much less with either passive scattered or 
pencil bean scanning protons in comparison with photon treat-
ment (24, 26).
Dosimetric comparisons taking into account the contribution 
of neutron scatter have concluded that PRT still delivers a reduced 
total integral dose when compared with photon irradiation (24). 
In an analysis of 30 patients with prostate cancer from Schneider 
et al. (27), the impact of X-ray scatter, neutron radiation, and the 
primary dose distribution on secondary cancer incidence were 
analyzed for convention and intensity-modulated photon plans 
as well as spot scanning PRT. After considering both primary 
dose and scatter dose contributions, it was estimated that the use 
of spot-scanned protons reduced the secondary cancer incidence 
by as much as 50% when compared with photon therapy (27). 
Pencil beam scanning PRT may provide the greatest opportunity 
to reduce the impact of neutron scatter on secondary malignancy 
risk as the out-of-field neutron dose produced by a scattered 
proton beam has been estimated to be more than 100 times that 
off a scanned proton beam (28). However, secondary malignancy 
risk due to scatter radiation from passively scattered proton beam 
treatment remains low. A study evaluating the total lifetime risk 
of a second cancer from stray radiation alone to be 1.5% for 
passively scatter craniospinal proton treatment and 0.8% for 
scanned craniospinal proton treatment (29). And when taking 
TABLe 1 | Secondary malignancy outcome data in pediatric patients 
treated with proton radiotherapy.
Reference Diagnosis N Follow-up  
median  
(range)
Secondary  
solid tumor 
incidence (%)
Yock et al. (31) Medulloblastoma 59 7 years (3.9–10.3) 0
Greenberger 
et al. (35)
Low-grade glioma 32 7.6 years (3.2–18.2) 0
Sethi et al. (33) Retinoblastoma 55 6.9 years (1.0–24.4) 5a
MacDonald 
et al. (34)
Ependymoma 70 3.8 years (1–11.7) 0
Ladra et al. 
(37)
Rhabdomyosarcoma 57 3.9 years (1.2–8.5) 0
Rombi et al. 
(36)
Ewings sarcoma 30  3.2 years (1.5–7.4) 0b
aOne patient with bilateral retinoblastoma developed a non-metastatic osteosarcoma 
of the femur.
bFour patients developed secondary hematologic malignancies.
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into account the therapeutic radiation as well as scatter radiation 
dose, passively scattered and scanned proton beam treatment 
similarly reduced the secondary cancer risk in comparison with 
IMRT photon treatment (29).
CLiniCAL DATA
Clinical data comparing the secondary malignancy incidence 
in long-term survivors following proton and photon therapy 
are limited given the significant follow-up time necessary to 
effectively evaluate radiation induced malignancy. However, a 
reduced incidence of radiation induced second cancer with PRT 
as compared to photon therapy has been reported in multiple 
series with early follow-up. Chung et al. (30) performed a large 
case matched comparison of 588 patients treated with PRT at the 
Harvard cyclotron from 1973 to 2001 and 588 patients treated 
with photon therapy from the Surveillance, Epidemiology, and 
End Results Program. Patients were matched with respect to age 
at radiation treatment, sex, year of treatment, cancer histology, 
and treatment site, and the median follow-up time was 6.7 years 
for proton patients and 6.0 years for photon patients. The major-
ity of patients were adults with tumors of the prostate, central 
nervous system or head-and-neck region. The crude rate of 
second malignancies was 5.2% among the proton cohort (29 
patients) vs. 7.5% in photon cohort (42 patients). On multi-
variable analysis, PRT was associated with a decreased risk of 
second malignancy [adjusted hazard ratio, 0.52 (95% confidence 
interval, 0.32–0.85), p =  0.009] when compared with photon 
therapy (30).
Multiple clinical series of pediatric patients have reported 
excellent outcomes with very low rates of second malignancies 
after PRT (Table 1). Among a prospective phase II study of PRT 
for 59 children with medulloblastoma and a median follow-up 
of 7  years (range 3.9–10.3), no patients have suffered from a 
second malignancies (31). The results from the 45 standard 
risk patients from this phase II study were then compared to a 
case matched series of 43 patients treated with photons over a 
similar time period (32). Three patients from the photon cohort 
experienced a second malignancy, including an astrocytoma, 
intracranial desmoid tumor, and thyroid cancer occurring 12.9, 
3.7, and 12.7  years after treatment, respectively, while none 
of the proton patients developed a second tumor (32). Sethi 
et  al. (33) retrospectively analyzed the incidence of second-
ary malignancy among patients treated with either proton or 
photon therapy for retinoblastoma. After a median follow-up 
of 6.9  years (range, 1.0–24.4  years) for the 55 patients in the 
proton cohort and 13.1 years (range, 1.4–23.9 years) for the 31 
patients in the photon cohort, the 10-year cumulative incidence 
of RT-induced or in-field second malignancies was significantly 
less among the proton cohort (0 vs. 14%, p = 0.015) (33). One 
proton patient with bilateral retinoblastoma did develop an 
out-of-field osteosarcoma of the femur (33). Other proton series 
among children with ependymoma (34), low-grade glioma (35), 
Ewing’s sarcoma (36), and rhabdomyosarcoma (37) have also 
reported no cases of PRT associated solid tumors (Table  1) 
after limited follow-up. Though longer follow-up is required 
for effective secondary malignancy risk comparison between 
proton and photon radiotherapy, these early clinical reports 
suggest a reduced incidence of radiation induced secondary 
cancers with PRT.
COnCLUSiOn
Multiple dosimetric studies have demonstrated the ability of 
PRT to deliver efficacious target volume coverage while reduc-
ing the total integral dose delivered to normal tissues when 
compared with photon therapy. Modeling systems taking into 
account these dosimetric comparisons, organ equivalent dose 
and radiation protection models have predicted a significantly 
reduced risk of secondary malignancy with PRT among multiple 
pediatric and adult malignancies. Though neutron scatter may 
be higher in tissues outside of the target volume with proton 
treatment, the secondary dose contribution is small and thus the 
total integral dose remains less with protons than with photon 
therapy. Pencil beam scanning systems provide the greatest 
opportunity to reduced secondary dose from neutron scatter 
and further reduced the secondary malignancy risk from proton 
treatment. Though clinical data are limited, early reports of 
prospective and retrospective series suggest a reduced incidence 
of secondary malignancy in patients treated with protons, and 
further analyses with longer follow-up are awaited. The data sup-
port the continued use of PRT in effort to reduce the incidence 
of secondary malignancies among children and adults expected 
to survive their disease.
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